1Wu F, Ames R, Clearwater J, et al. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women including the effect of hormone replacement therapy. Clin Endocrinol(OxF) 2002; 56(6):703 - 11
2Michaelsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: Population based case-control study. Br Med 1998; 316(7148): 1858-63
3Bemben DA, Landon DB. Relationship between estrogen use and musculoskeletal function in postmenopausal women. Maturitas 2002 ;42 (2): 119 -27
4Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the ratio of bone loss after discontinuation of treatment of postmenopausal osteoporosis. Ann Intern Med 2002;137(11): 875 -83
5Greendale GA, Espeland M, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy. Arch Intern Med 2002; 162(6):665 - 72
6Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopansal women. JAMA 2002; 287 ( 20 ): 2668 - 76
7Cummings SR, Yankov V, Ensrud K, et al. Ultralow estradiol increases BMD and decreases bone turnover in older women, particularly those with undetectable estradiol: the ULTRA trial. J Bone Miner Res 2003; 18 (Suppl 2): S53
8Greenspan SL, Resnick NM, Parker RA, et al. Combination therapy for prevention/treatment of osteoporosis in elderly women: a randomized, double-blind,placebo-controlled, NIH-sponsored clinical trial. J Bone Miner Res 2002; 17(Suppl 1): S135
9Grodstein F, Manson JE, Colditz GA, et al. A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133(12): 933 -41
10Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998; 280(7): 605 - 13
